Kura Oncology, Inc. (NASDAQ:KURA) Given Consensus Rating of "Buy" by Analysts

Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) has earned a consensus rating of "Buy" from the eleven research firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a hold recommendation, nine have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $29.38.

KURA has been the topic of a number of research reports. Stifel Nicolaus downgraded Kura Oncology from a "buy" rating to a "hold" rating and reduced their price objective for the stock from $26.00 to $19.00 in a research note on Monday, October 14th. Jefferies Financial Group cut their target price on shares of Kura Oncology from $32.00 to $28.00 and set a "buy" rating for the company in a report on Thursday, November 21st. Wedbush reiterated an "outperform" rating and set a $37.00 price objective on shares of Kura Oncology in a research report on Monday, November 4th. StockNews.com cut shares of Kura Oncology from a "hold" rating to a "sell" rating in a research note on Wednesday, November 20th. Finally, HC Wainwright upped their target price on shares of Kura Oncology from $32.00 to $37.00 and gave the company a "buy" rating in a research report on Thursday, November 21st.

Kura Oncology Price Performance

Shares of KURA stock traded down $0.23 during trading hours on Thursday, hitting $10.71. The stock had a trading volume of 1,610,289 shares, compared to its average volume of 1,045,636. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. The stock has a market capitalization of $832.81 million, a price-to-earnings ratio of -4.54 and a beta of 0.75. Kura Oncology has a one year low of $9.68 and a one year high of $24.17. The stock's 50-day moving average price is $16.21 and its two-hundred day moving average price is $19.04.

Institutional Trading of Kura Oncology

Several institutional investors have recently added to or reduced their stakes in the company. Franklin Resources Inc. grew its stake in shares of Kura Oncology by 1.5% during the third quarter. Franklin Resources Inc. now owns 1,588,401 shares of the company's stock valued at $28,687,000 after buying an additional 23,113 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Kura Oncology by 2.4% during the 3rd quarter. Geode Capital Management LLC now owns 1,780,509 shares of the company's stock valued at $34,798,000 after acquiring an additional 41,535 shares during the period. Barclays PLC grew its position in Kura Oncology by 104.5% in the 3rd quarter. Barclays PLC now owns 165,484 shares of the company's stock valued at $3,234,000 after acquiring an additional 84,563 shares during the last quarter. Jane Street Group LLC increased its stake in Kura Oncology by 36.7% in the third quarter. Jane Street Group LLC now owns 126,085 shares of the company's stock worth $2,464,000 after purchasing an additional 33,848 shares during the period. Finally, Point72 DIFC Ltd bought a new stake in shares of Kura Oncology during the third quarter worth $146,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.